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Abstract 
Loss of estrogen receptor α (ERα) expression and gain of TWIST (TWIST1) expression in 
breast tumors correlate with increased disease recurrence and metastasis and poor dis-
ease-free survival. However, the molecular and functional regulatory relationship between 
TWIST and ER are unclear. In this study, we found TWIST was associated with a chromatin 
region in intron 7 of the human ESR1 gene coding for ER. This association of TWIST effi-
ciently recruited the nucleosome remodeling and deacetylase (NuRD) repressor complex to 
this region, which subsequently decreased histone H3K9 acetylation, increased histone H3K9 
methylation and repressed ESR1 expression in breast cancer cells. In agreement with these 
molecular events, TWIST expression was inversely correlated with ER expression in both 
breast cancer cell lines and human breast ductal carcinomas. Forced expression of TWIST in 
TWIST-negative and ER-positive breast cancer cells such as T47D and MCF-7 cells reduced 
ER expression, while knockdown of TWIST in TWIST-positive and ER-negative breast 
cancer cells such as MDA-MB-435 and 4T1 cells increased ER expression. Furthermore, 
inhibition of histone deacetylase (HDAC) activity including the one in NuRD complex sig-
nificantly increased ER expression in MDA-MB-435 and 4T1 cells. HDAC inhibition together 
with TWIST knockdown did not further increase ER expression in 4T1 and MDA-MB-435 
cells. These results demonstrate that TWIST/NuRD represses ER expression in breast 
cancer cells. Therefore, TWIST may serve as a potential molecular target for converting 
ER-negative breast cancers to ER-positive breast cancers, allowing these cancers to re-
store their sensitivity to endocrine therapy with selective ER antagonists such as tamoxifen 
and raloxifene. 
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Introduction 
TWIST,  also  known  as  TWIST1,  is  a  class  II 
member  of  the  basic  helix-loop-helix  (bHLH)  tran-
scription  factor  family.  During  embryonic  develop-
ment, TWIST plays an essential role in specification of 
the  mesoderm  and  differentiation  of  the  meso-
derm-derived  tissues.  During  carcinogenesis  TWIST 
expression is activated in a subset of breast, gastric, 
hepatocellular, prostate and bladder cancers, and its 
upregulation in these cancers usually correlates with 
low  levels  of  E-cadherin  expression,  high  levels  of 
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cancer aggressiveness and poor patient survival rates 
(1). TWIST expression in cancer cells is usually asso-
ciated  with  cell  survival,  angiogenesis,  epitheli-
al-mesenchymal  transition  (EMT),  metastasis,  and 
drug resistance (2-4). Recent studies also suggest that 
TWIST expression may increase the subpopulation of 
breast cancer stem-like cells in culture, which may be 
relevant to drug resistance and distant metastasis (2, 
5,  6).  Mechanistically,  TWIST  has  been  shown  to 
promote EMT, cell migration, invasion and metastasis 
by upregulating the expression of AKT2 (7), SNAIL1, 
SNAIL2 and PDGF receptor- (4, 8, 9) and downreg-
ulating the expression of E-cadherin (2, 10, 11). Our 
recent  study  further  demonstrated  that  TWIST  di-
rectly interacts with multiple components of the nu-
cleosome  remodeling  and  deacetylase  (NuRD)  gene 
repression complex. Through direct association with 
the  E-boxes  proximate  to  the  E-cadherin  gene  pro-
moter, TWIST effectively recruits the NuRD complex 
to repress E-cadherin expression, which significantly 
promotes EMT, migration, invasion and metastasis of 
beast  cancer  cells  (10).  In  addition,  it  has  been  re-
ported that coexpression of ErbB2 or H-RasV12 with 
TWIST could significantly enhance TWIST-mediated 
EMT and override the Ras oncogene-induced prem-
ature cell senescence (12). Our study revealed that the 
Ras-activated MAPKs phosphorylate TWIST protein 
at serine 68, leading to stabilization of TWIST protein 
and enhancement of its function in induction of EMT 
and cell invasiveness in breast cancer cells (13). 
Breast cancer is the most common cancer type in 
women (14). The estrogen receptor α (ERα) protein 
coded by the ESR1 gene plays an important role in 
regulation  of  mammary  epithelial  cell  proliferation, 
differentiation  and  tumorigenesis  (15).  Since  estro-
gen-activated  ER  induces  mammary  epithelial  cell 
proliferation,  elevated  estrogen  or  ER  activity  is  a 
risk factor in development of breast cancer and ER 
function  is  a  survival  factor  in  estrogen-dependent 
ER-positive  breast  cancer  cells.  Thus,  inhibition  of 
ER function in breast cancer cells by selective ER 
modulators (SERMs) such as tamoxifen and raloxifene 
serves as an effective endocrine therapy to treat es-
trogen  sensitive  breast  cancers  (16).  However,  most 
breast  cancers  treated  with  endocrine  therapy  will 
develop resistance to anti-ER treatment. One reason 
for developing such kind of resistance is attributed to 
the loss of the expression of ER and other epithelial 
marker genes such as E-cadherin through EMT pro-
cess. Loss of ER and gain of EMT features are also 
usually associated with development of resistance to 
chemotherapy  and  poor  survival  rate  (17).  Genetic 
deletion or mutation of the ESR1 gene is not common; 
instead, loss of ER expression is mostly due to tran-
scriptional  repression  by  histone  modifications  and 
DNA methylation (18). EMT can be induced by mul-
tiple  signaling  pathways  such  as  TGF-/SMADs, 
Wnt/-catelin and hypoxia/HIF1 signaling pathways 
and a group of transcription factors including TWIST, 
SNAIL, SLUG, Zeb1 and SIP1 that repress E-cadherin 
expression and enhance tumor cell migration, inva-
sion and metastasis (19, 20). However, the crosstalk 
mechanisms between the loss of ER expression and 
the EMT process are poorly understood.  
 In this study, we found that TWIST expression is 
inversely  correlated  with  ER  expression  in  breast 
cancer  cell  lines  and  human  breast  invasive  ductal 
carcinomas. TWIST interacts with the NuRD complex 
and recruits this gene repression complex to a chro-
matin region of the human ESR1 gene to repress ER 
expression  in  ER-negative  breast  cancer  cells. 
Knockdown of TWIST in these cells resulted in ER 
expression. 
Materials and Methods 
Cell lines and plasmids 
The  doxycycline-inducible  HEK293  cell  lines 
with stable Flag-TWIST or Flag expression were gen-
erated  and  maintained  as  described  previously  (10, 
13). Stable 4T1 and MDA-MB-435 cell lines expressing 
a non-targeting shRNA or specific shRNAs that target 
TWIST mRNAs were also described previously (10). 
A  332-bp  DNA  fragment  spanning  the 
TWIST-binding region in intron 7 of the human ESR1 
gene was amplified by PCR from a human genomic 
DNA  sample  using  primers  ESR1-BamH1-F 
(5’-cgcggatccGGGGGGAGGTTCTTCTTC)  and 
ESR1-SalI-R  (5’-  acgcgtcgacTTATTGCTCAGAAA-
TAGTCATG).  This  amplified  DNA  fragment  was 
subcloned  into  the  pGL3-Pro-Luc  vector  (Promega) 
for  constructing  the  pGL-332ESR1-Pro-Luc  reporter 
plasmid. The cloned DNA fragment was validated by 
DNA sequencing.  
Chromatin immunoprecipitation (ChIP) and 
ChIP-Sequencing (ChIP-Seq) assays 
ChIP assay was performed as described previ-
ously (10, 21). Briefly, the Flag-Twist and Flag control 
HEK293 cells were cultured in 15-cm plates to 65% 
confluence and treated with 0.1 μg/ml of doxycycline 
for 16 hours. MDA-MB-435 cells with TWIST shRNA 
or non-targeting shRNA expression were cultured in 
15-cm  plates  to  almost  100%  confluence.  The  cells 
were cross-linked with formalin and lysed in 1 ml of 
cell  lysis  buffer  containing  protease  inhibitors.  The 
lysates were centrifuged at 3000g for 5 minutes. The Int. J. Biol. Sci. 2012, 8 
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pellets were washed and then re-suspended in 600 µl 
of  solution  with  protease  inhibitors  and  sonicated. 
The supernatants were pre-cleaned and diluted with 
1.4 ml of solution containing 2 mM EDTA, 100 mM 
NaCl,  20  mM  Tris-HCl  (pH  8.0),  0.5%  Triton  X-100 
and protease inhibitors. Each aliquot of 0.4 ml sam-
ples was mixed with 6 µl of M2 Flag antibody beads or 
specific  antibodies  against  TWIST,  MTA2,  HDAC2, 
Mi2, acetylated histone H3K9 and methylated histone 
H3K9. The mixtures were incubated overnight at 4oC 
with rotation. The beads were sequentially washed in 
ChIP I, II and III buffers and the TE buffer containing 
1 mM DTT. The protein-DNA complexes were eluted 
and digested with 5 µg of proteinase K overnight at 
65oC to release DNA from cross-linked proteins. The 
DNA was cleaned by phenol and chloroform extrac-
tion, precipitated and dissolved in 20 µl of ddH2O for 
PCR analysis. 
For  ChIP-re-ChIP  assays,  the  above  ChIP  III 
buffer-washed antibody beads were further washed 
by  Tris-buffered  saline  and  eluted  using  a  3×Flag 
peptide solution. The eluted materials  were diluted 
and  subjected  to  the  re-ChIP  step  using  antibodies 
against MTA2, HDAC2 or Mi2 and the protein A/G 
beads. The recovered DNA samples from ChIP and 
ChIP-re-ChIP were analyzed by quantitative real time 
PCR  using  three  primer  pairs.  Primers  P3  (5’ 
agctgggctcactcacacat-3’)  and  P4  (5’-gaggcatag 
agcagagtcacc-3’)  were  used  to  detect  the  TWIST 
binding region mapped in intron 7 of the human ESR1 
gene.  Primers  P1  (5’-tcacaccttgcttcgcatag-3’)  and  P2 
(5’-tgagctcagaaatccacttcc-3’)  were  used  to  detect  a 
negative control region in intron 1 of the ESR1 gene. 
Primers  P5  (5’-  acctgtgagcagggtgactt-3’)  and  P6  (5’- 
acaaaaacccgcaacttcct-3’) were used to detect a nega-
tive control region located 3’ to the ESR1 gene. 
For ChIP-Seq analysis, crosslinked DNA-protein 
samples  were harvested from Flag-TWIST and Flag 
HEK293 cells and sonicated into 200-500 bp in length 
of DNA fragments. The prepared samples were im-
munoprecipitated using the M2 Flag antibody beads. 
The washed beads were eluted with a 3×Flag peptide 
solution  and  the  yielded  DNA  fragements  were  li-
gated to oligo adapters using T4 DNA ligase for PCR 
to  establish  DNA  libraries.  The  libraries  were  pro-
cessed for massively parallel sequencing at the Hu-
man Genome Sequencing Center at Baylor College of 
Medicine. The Flag-TWIST binding sites were deter-
mined after subtracting the Flag-binding background. 
Sequencing reads were mapped onto the Human Mar. 
2006 Assembly (hg18) using BWA (22) and the peaks 
are identified using MACS (23) and visualized with 
the  Integrated  Genome  Browser  (IGB) 
(http://www.affymetrix.com/partners_programs/pr
ograms/developer/tools/download_igb.affx). 
Breast tumors and total RNA isolation 
A total of 28 human breast invasive ductal car-
cinoma specimens were collected from surgically re-
moved tumor tissues at Luzhou Medical College Af-
filiated Hospital in China with informed consent. All 
protocols were approved by Luzhou Medical College. 
All patients were Chinese women and aged from 33 to 
72 years old. No patient survival data were available 
at  this  stage.  The  tumor  tissues  were  immediately 
frozen in liquid nitrogen  and stored at  -80oC. Total 
RNA was isolated from tumor tissues and cultured 
cells using the TRIZOL reagent and stored at  -80oC 
(Invitrogen). 
Analysis of mRNA expression by quantitative 
and semi-quantitative PCR 
 The cDNA libraries were generated using a re-
verse transcriptase kit (Invitrogen) from 1 g of total 
RNA. Real-time PCR was performed using the qPCR 
MasterMix  Plus  (Eurogentec)  and  the  StepOnePlus 
Real-Time PCR system (Applied Biosystems) as  de-
scribed  previously  (10,  21).  The  primers 
5’-tcctaacttgctcttggacagg-3’  and  5’-gtagccagcagca 
tgtcg-3’  and  the  TaqMan  probe  22  were  used  to 
measure ERα cDNA levels in the libraries. The pri-
mers  5’-gggccggagacctagatg-3’  and  5’-tttccaag 
aaaatctttggcata-3’  and  the  TaqMan  probe  50  were 
used to measure TWIST cDNA levels in the libraries.  
For  semi-quantitative  RT-PCR  using  breast  tu-
mor mRNA samples, reverse transcription and PCR 
were performed using the following mRNA-specific 
primers:  RT-ESR1-5  (5’-gtgcctggctagagatcctg)  and 
RT-ESR1-3  (5’-agagacttcagggtgctgga)  for  measuring 
ER  mRNA;  RT-TWIST-5  (5’-acgagctggactccaagatg) 
and RT-TWIST-3 (5’-cacgccctgtttctttgaat) for measur-
ing TWIST mRNA. The GAPDH mRNA was meas-
ured in the same reaction for each sample to serve as 
an  endogenous  control  for  normalizing  the  relative 
levels of ER and TWIST mRNAs. 
Western Blotting 
Western blotting analysis was performed as de-
scribed  previously  (10,  21).  Antibodies  for  TWIST1, 
E-cadherin, β-actin and HA-tag were used previously 
(10,  13),  anti-ERα  monoclonal  antibody  (D-12)  was 
purchased  from  Santa  Cruz  Biotechnology  (Santa 
Cruz, CA, USA). 
Luciferase reporter assay 
Cells were cultured to 40% confluence in 12-well 
plates and then co-transfected with indicated amount Int. J. Biol. Sci. 2012, 8 
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of  pGL3-Pro-Luc  or  pGL-332ESR1-Pro-Luc  reporter 
plasmid,  indicated  amount  of  pSG5-HA-TWIST 
plasmid or pSG5 empty plasmid and 30 ng of β-Gal 
expression plasmids using Lipofectamin 2000. Lucif-
erase  and  β-gal  activities  were  measured  at  2  days 
after transfection. The luciferase activity of each sam-
ple was normalized to the β-gal activity of the same 
sample.  All  experiments  were  performed  in  tripli-
cates. 
Immunohistochemical staining 
Immunohistochemistry was done on breast tu-
mor  sections  prepared  from  tumor  tissues  fixed  in 
10%  buffered  formalin  and  embedded  in  paraffin. 
Sections (4 μm thick) were deparaffinized in xylene 
and rehydrated in a series of diluted alcohol and dis-
tilled water. After antigen retrieval, endogenous pe-
roxidase  activity  was  blocked  with  0.3%  hydrogen 
peroxide  in  methanol  for  30  minutes,  followed  by 
rehydration in 1×PBS and incubation with 5% rabbit 
serum  for  30  minutes  to  block  nonspecific  back-
ground. The slides were then incubated overnight at 
4oC  with  a  TWIST  monoclonal  antibody  (ab  50887, 
abcam)  or  an  ERα  antibody  in  Tris-buffered  saline 
containing 2% of serum and 1% of bovine serum al-
bumin  (BSA).  The  washed  sections  were  incubated 
with appropriate secondary antibodies at dilution of 
1:100 for 30 minutes at room temperature and then 
incubated  with  peroxidase-conjugated  avidin-biotin 
complexes. The immunostaining signals were devel-
oped  by  DAB  staining.  The  sections  were  counter-
stained with hematoxylin and analyzed by standard 
light  microscopy.  Sections  incubated  with  TBS  con-
taining 2% rabbit serum and 1% BSA without primary 
antibody served as negative controls. 
Statistical analysis 
Paired  Student's  t-test  was  used  to  determine 
any  significant  differences.  P-value  ≤  0.05  was  con-
sidered to be significant. 
Results 
TWIST protein is associated with an intronic 
chromatin region of the human ESR1 gene 
 To identify potential TWIST-binding sites in the 
human genome, we performed ChIP-Seq analysis in 
previously described HEK293 cell lines that express 
either Flag-TWIST or Flag control (10). We indentified 
one TWIST association region within intron 7 of the 
human  ESR1  gene  (Fig.  1A).  This  binding  site  was 
centralized  at  bp  152458103  of  chromosome  6,  and 
TWIST  bound  at  this  site  was  enriched  highly  in 
Flag-TWIST cells versus Flag control cells. Sequence 
analysis  of  a  600  bp  region  located  up  and  down 
streams of the binding peak revealed six of the poten-
tial TWIST-binding E-boxes (CANNTG). ChIP analy-
sis using a pair of specific primers P3 and P4 spanning 
the  mapped  TWIST  binding  region  demonstrated 
more  than  1200-fold  enrichment  of  TWIST  in 
Flag-TWIST cells versus Flag control cells. However, 
TWIST was not enriched with the two regions used as 
negative controls, one in the first intron amplified by 
primers P1 and P2 and the other in a 3’ non-coding 
region amplified by primers P5 and P6 (Fig. 1A and 
B). Furthermore, ChIP assay performed with primers 
P3  and  P4  also  proved  that  the  endogenously  ex-
pressed  TWIST  protein  in  MDA-MB-435  cells  was 
specifically  and  efficiently  recruited  to  the  TWIST 
binding site located in the intron 7 of the human ESR1 
gene (Fig. 1C).  
 
 
Fig. 1. TWIST is associated with a chromatin region in 
intron 7 of the ESR1 gene. A. The ChIP-Seq map showed one 
TWIST  binding  site  located  in  intron  7  of  the  ESR1  gene  in 
Flag-Twist HEK293 cells. The peak value was obtained by nor-
malizing to the background, if any, in Flag HEK293 control cells. 
The locations of the ESR1 gene in chromosome 6 and the TWIST 
binding sites are indicated. The locations of primer pairs used for 
ChIP assays are also indicated. B. ChIP assays were performed 
using Flag-TWIST (FT) and Flag (F) HEK293 cells and Flag antibody 
beads. Precipitated DNA was assayed by PCR using three pairs of 
primers indicated in panel A. Data obtained from Flag-TWIST cells 
were normalized with that from Flag control cells. C. ChIP assay in 
MDA-MB-435 cells with endogenously expressed TWIST. ChIP 
assay was performed using TWIST antibody or using non-immune 
IgG as a negative control. The precipitated DNA was assayed by 
PCR using primers P3 and P4 shown in panel A. 
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The NuRD repression complex is recruited to 
the TWIST-binding region of the human ESR1 
gene 
 We have previously shown that TWIST interacts 
and recruits the NuRD complex to a promoter region 
of the E-cadherin gene in breast cancer cells (10). To 
examine whether the components of NuRD complex 
are  also  recruited  to  the  TWSIT  binding  site  of  the 
ESR1 gene in HEK293 cells expressing Flag-TWIST, 
we performed sequential ChIP-re-ChIP assays using 
the Flag antibody in the first step ChIP, followed by 
the second step ChIP using antibodies specific to in-
dividual NuRD complex components, including Mi-2, 
MTA2  and  HDAC2.  HEK293  cells  expressing  Flag 
were side-by-side assayed as a background control. 
This  experiment  revealed  a  100-fold  enrichment  of 
TWIST-associated  Mi-2,  MTA2  and  HDAC2  at  the 
TWIST binding site of the ESR1 gene in Flag-TWIST 
cells over the Flag control cells (Fig. 2A). This indi-
cates  that  TWIST  can  efficiently  recruit  the  NuRD 
complex to the TWIST-binding site of the ESR1 gene 
in HEK293 cells. 
 Next, we used ER-negative MDA-MB-435 cells 
to  check  the  recruitment  of  NuRD  complex  by  the 
endogenous TWIST to the TWIST-binding site of the 
ESR1 gene. Indeed, TWIST and multiple NuRD com-
plex  components  including  MTA2,  HDAC2  and 
RbAp46  were  found  to  be  associated  with  the 
TWIST-binding site of the ESR1 gene in MDA-MB-435 
cells that express non-targeting shRNA, while these 
recruitments  were  significantly  reduced  in 
MDA-MB-435  cells  with  shRNA-mediated  stable 
knockdown of TWIST (Fig. 2B). These MDA-MB-435 
cell  lines  expressing  either  non-targeting  shRNA  or 
TWIST mRNA-targeting shRNA were described pre-
viously (10). These results demonstrate that the core 
components of NuRD complex are indeed recruited to 
the TWIST-binding site of the ESR1 gene by interac-
tion with TWIST.  
 To evaluate the effects of recruited NuRD com-
plex on the epigenetic changes of chromatin around 
the TWIST-binding site of the ESR1 gene, we exam-
ined the levels of histone acetylation and methylation 
by ChIP assays. Although both chromatin-associated 
histone H3K9 acetylation and mono-methylation were 
detected  in  the  MDA-MB-435  cells  expressing 
non-targeting  shRNA,  the  acetylated  histone  H3K9 
and  the  mono-methylated  histone  H3K9  were  in-
creased  and  decreased,  respectively,  in  the 
MDA-MB-435 cells with TWIST knockdown (Fig. 2C). 
These  results  demonstrate  that  TWIST-mediated  re-
cruitment of NuRD complex is consistent with a re-
pressed  epigenetic  chromatin  modification  in  the 
TWIST-binding chromatin region of the ESR1 gene.  
 
 
 
Fig.  2.  TWIST  recruits  NuRD  complex  to  the 
TWIST-binding  site  of  the  ESR1  gene.  A.  ChIP-re-ChIP 
assays were performed with Flag HEK293 (F) and Flag-TWIST 
HEK293 (FT) cells using the Flag antibody beads in the first step 
ChIP and the antibodies against Mi2, MTA2 or HDAC2 in the 
second step ChIP. The precipitated DNA from the second step 
ChIP  was  assayed by  real  time  PCR  using  primers  P3  and  P4 
indicated  in  Fig.  1A.  B.  MDA-MB-435  cells  expressing 
non-targeting shRNA (shCtrl) or shRNA targeting TWIST mRNA 
(shT) were used in ChIP assays with antibodies against TWIST, 
MTA2,  HDAC2  or  RbAp46  as  indicated.  Real-time  PCR  was 
performed as panel A. C. MDA-MB-435 cells with shCtrl or shT 
were used in ChIP assays with antibodies against acetylated or 
methylated histone H3K9 as indicated. Real-time PCR was per-
formed as panel A. 
 
TWIST represses ERα expression  
 Based  on  the  association  of  TWIST  with  the 
ESR1  gene  and  TWIST-mediated  recruitment  of  the 
NuRD complex for gene repression, we hypothesized 
that TWIST plays an important role in suppression of Int. J. Biol. Sci. 2012, 8 
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ER expression in breast cancer cells. To test this hy-
pothesis, we first measured ER mRNA and protein 
levels in several breast cancer cell lines by real-time 
RT-PCR  and  Western  blot  analysis.  High  levels  of 
TWIST  mRNA  and  protein  were  detected  in  the 
ER-negative SUM1315 and MDA-MB-435 cell lines, 
and a low level of TWIST protein was also detected in 
the ER-negative MDA-MB-231 cell line. In contrast, 
TWIST mRNA and protein were undetectable in T47D 
and MCF-7 cells that express high levels of ER (Fig. 
3A and B). These results indicate that TWIST expres-
sion is negatively correlated with ER expression in 
these  cell  lines.  Since  the  three  TWIST-positive  cell 
lines are poorly differentiated metastatic cell lines and 
the  two  TWIST-negative  cell  lines  are  much  more 
differentiated non-metastatic cell lines as assayed in 
xenograft mouse models, repression of ER expres-
sion by TWIST may also contribute to the progression 
of breast cancer to an EMT and metastatic stage. 
 Next,  we  amplified  a  332  bp  DNA  fragment 
containing the six E-Boxes within the TWIST-binding 
region from human ESR1 gene, cloned this fragment 
into the pGL3-Pro plasmid with a basal promoter and 
a  luciferase  reporter  coding  sequences.  After  this 
pGL3-332ESR1-Pro-Luc  reporter  plasmid  was 
co-transfected with a TWIST expression vector  or a 
parent  control  vector  into  HEK293T  cells,  we  ob-
served  that  overexpression  of  TWIST  significantly 
repressed  the  activity  of  this  reporter.  In  contrast, 
overexpression of TWIST did not repress the activity 
of  the  pGL3-Pro-Luc  parent  reporter  without  the 
332ESR1 sequence (Fig. 4A). These results suggest that 
the TWIST/NuRD-associated region of the ESR1 gene 
has a transcriptional repression function.  
 Furthermore, we addressed whether TWIST ex-
pression would repress endogenous ER expression 
in  TWIST-negative  and  ER-positive  breast  cancer 
cells such as T47D and MCF-7 cell lines. Our experi-
ments demonstrated that forced expression of TWIST 
indeed  repressed  ER  mRNA  expression  in  T47D 
cells and reduced ER protein  level in MCF-7 cells 
(Fig. 4B and C). In agreement with our previous re-
port (10), forced expression of TWIST in MCF-7 cells 
significantly reduced the level of E-cadherin protein 
(Fig. 4C). Conversely, we also tested whether knock-
down of TWIST expression would result in ER ex-
pression in TWIST-positive and ER-negative breast 
cancer  cells,  including  MDA-MB-435  and  4T1  cell 
lines.  Our  analysis  revealed  that  knockdown  of 
TWIST in both of these cell lines increased 2.5-3 folds 
of ER mRNA expression (Fig. 4D). Accordingly, the 
ER protein levels in 4T1 and MDA-MB-435 cells with 
non-targeting shRNA expression were extremely low, 
while knockdown of TWIST expression in these cells 
markedly increased ER protein in these cells (Fig. 4E, 
lanes 1, 3, 5 and 7). Since the NuRD complex recruited 
by  TWIST  contains  histone  deacytalases  such  as 
HDAC2  (10,  24),  we  tested  whether  Trichostain  A 
(TSA),  a  HDAC  inhibitor,  could  inhibit 
TWIST/NuRD-mediated  repression  of  ER  expres-
sion.  Importantly,  both  TSA-treated  4T1  and 
MDA-MB-435  cells  with  non-targeting  shRNA  ex-
pressed much higher levels of ER protein compared 
with  their  respective  vehicle-treated  control  groups 
(Fig. 4E, compare lane 1 with lane 2 and lane 5 with 
lane 6). In the TSA-treated 4T1 and MDA-MB-435 cells 
with shRNA-mediated TWIST knockdown, ER pro-
tein showed no significant further increase (Fig. 4E, 
compare the ratios of ER to -actin in lane 4 with 
lanes 2 and 3 and in lane 8 with lanes 6 and 7), sug-
gesting that either knockdown TWIST or inhibition of 
NuRD  HDAC  activity  can  effectively  relieve  the 
transcriptional repression of the ESR1 gene. 
 
Fig. 3. TWIST expression is inversely correlated with ERα expression in human breast cancer cell lines. A. Real-time 
RT-PCR analysis for the mRNA levels of TWIST (T) and ERα (E) in SUM1315, MDA-MB-435 (MDA435), MDA-MB-231 (MDA231), T47D 
and MCF-7 human breast cancer cell lines. The data were normalized to the mRNA levels of GAPDH and presented as average  standard 
deviation. B. Western blot analysis for TWIST and ER in the above human breast cancer cell lines. β-actin was assayed as a control for 
the loaded total cellular proteins.  Int. J. Biol. Sci. 2012, 8 
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Fig. 4. TWIST represses ERα expression. A. 293T cells were transiently co-transfected with 120 ng of HA-TWIST expression 
plasmid or parent control plasmid DNA and 50 ng of pGL3-332ESR1-Pro-Luc or pGL-Pro-Luc reporter plasmid DNA as indicated. 
Western blot analysis using antibodies against HA and -actin (lower panel) and luciferase activity assay (upper panel) were performed in 
triplicates. **, p < 0.001. B. T47D cell lines with control parent vector (T47D/V) and TWIST expression vector (T47D/T) were estab-
lished. The levels of TWIST and ER mRNAs were measured by real time RT-PCR. **, p < 0.001. C. Western blot analysis for ER, 
E-cadherin, TWIST and -actin in MCF-7 cells transfected with a control parent vector or a TWIST expression vector. D. Measurement 
of ER mRNA levels by real-time RT-PCR in 4T1 and MDA-MB-435 (MDA435) cells expressing a non-targeting shRNA (shCtrl) or an 
shRNA targeting TWIST mRNA (shT). **, p < 0.001. E. The 4T1 and MDA-MB-435 cells with TWIST knockdown (shTWIST) or control 
shRNA (shCtrl) were treated with vehicle (-) or 330 nM of TSA (+) as indicated. Western blot analysis was performed using antibodies 
against ER and -actin. 
 
TWIST expression is negatively associated 
with ERα protein expression in human breast 
tumors 
To examine the effect of TWIST on ER expres-
sion  in  human  breast  tumors,  we  performed 
semi-quantitative  RT-PCR  and  immunohistochemis-
try to measure TWIST and ER mRNA and proteins 
in  a  total  of  28  invasive  breast  ductal  carcinomas. 
Representative results are shown in Fig. 5A and B. By 
analyzing data obtained from these assays we identi-
fied  17  (61%)  tumors  with  high  levels  of  TWIST 
mRNA  and  protein  and  very  low  or  undetectable 
levels of ER mRNA and protein, 7 (25%) tumors with 
very low or undetectable levels of TWIST mRNA and 
protein and high levels of ER, 2 (7%) tumors with 
high levels of both TWIST and ER mRNA and pro-
teins and 2 (7%) tumor with very low or undetectable 
levels of both TWIST and ER mRNA and proteins 
(Fig. 5C). These results indicate that TWIST expres-
sion  is  inversely  correlated  with  ER  expression  in 
most (85.7%) of the invasive breast carcinomas. 
Discussion 
Most of the breast cancers initially express ER 
and depend on estrogen to grow. However, some of 
these  ER-positive  breast  cancers  lose  ER  and  ac-
quire  an  estrogen-independent  feature  during  pro-
gression (16, 17). Because ER-positive breast cancers 
have  a  better  prognosis  and  are  more  likely  to  re-
spond to endocrine therapy with SERMs such as ta-
moxifen and raloxifene compared with ER-negative 
breast  cancers,  the  loss  of  ER  and  the  gain  of  re-
sistance  to  endocrine  therapy  represent  a  daunting 
challenge  to breast cancer treatment. Therefore, un-
derstanding  the  molecular  mechanisms  responsible 
for repression of ER expression may help to restore 
ER expression and endocrine therapy sensitivity in 
ER-negative breast cancers.  
In this study, we demonstrated that TWIST ex-
pression is inversely correlated with ER expression 
in both breast cancer cell lines and human breast in-
vasive ductal carcinomas, suggesting a potential reg-
ulatory relationship between these two proteins. More Int. J. Biol. Sci. 2012, 8 
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importantly,  expression  of  TWIST  in  ER-positive 
breast cancer cells significantly reduced ER levels, 
while knockdown of TWIST in ER-negative breast 
cancer cells caused re-expression of endogenous ER. 
These results further supported the notion that TWIST 
may directly repress ER expression and contribute to 
breast cancer progression not only in the induction of 
EMT but also in the conversion of breast cancer from 
an ER-positive and endocrine therapy-sensitive sta-
tus  to  an  ER-negative  and  endocrine  thera-
py-resistent status. 
 
 
Fig. 5. TWIST expression inversely correlates with the levels of ERα protein in human breast invasive ductal carci-
nomas. A. Semi-quantitative analysis of ERα, TWIST and GAPDH mRNA expression by RT-PCR in human breast invasive ductal car-
cinomas. A total of 28 independent tumor mRNA samples were assayed with three repeat experiments and a part of the representative 
results is shown. B. Immunohistochemistry analysis (brown color) for TWIST and ER in human breast invasive ductal carcinomas. Tissue 
sections prepared from the 28 human invasive breast ductal carcinomas were immunostained with TWIST and ER antibodies. Repre-
sentative results obtained from two tumors are shown. Photos were taken under a microscope set at 400×magnification. C. A summary 
of the data according to TWIST and ER immunohistochemistry in the 28 human invasive breast ductal carcinomas. Int. J. Biol. Sci. 2012, 8 
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Indeed, our  molecular analyses provided com-
pelling evidence for direct repression of ER expres-
sion  by  TWIST.  First,  we  identified  a  functional 
TWIST binding region in intron 7 of the ESR1 gene by 
an  unbiased  ChIP-Seq  approach  and  validated  the 
association of TWIST with this site by ChIP assay in 
breast cancer cells with endogenous TWIST expres-
sion.  Furthermore,  the  DNA  region  associated  with 
TWIST contains multiple E-Boxes for TWIST binding 
and it indeed mediates TWIST-dependent repression 
of the transcriptional activity of a heterologous pro-
moter  linked  with  a  luciferase  reporter.  Moreover, 
through binding to the chromatin region of the ESR1 
gene  and  interacting  with  the  components  of  the 
NuRD  complex,  TWIST  effectively  recruits  NuRD 
complex  to  repress  ER  expression.  This  result  is 
consistent with our previous finding that TWIST can 
recruit  NuRD  complex  to  the  E-cadherin  promoter 
and repress E-cadherin expression to promote EMT 
and breast cancer metastasis (10). Finally, we demon-
strated  that  the  recruitment  of  NuRD  complex  de-
creased histone H3K9 acetylation and increased H3K9 
methylation; inhibition of HDAC activity resulted in 
ER expression in ER-negative breast cancer cells. 
These  findings  are  consistent  with  the 
TWIST-mediated  gene  repression  function.  Taken 
together, these results demonstrate that ESR1 gene is a 
direct target gene of TWIST and TWIST can recruit 
NuRD complex to directly repress ER expression in 
breast cancer cells (Fig. 6). 
Both SUM1315 and MDA-MB-435 cells express 
relatively high-level TWIST protein, while other types 
of cells examined in this study express either a low 
level or no TWIST. Because SUM1315 breast cancer 
cells grow slowly, most experiments were performed 
in MDA-MB-435 cells. We are fully aware of that the 
origin  of  the  MDA-MB-435  cell  line  was  somewhat 
controversial. It was initially described and used as a 
metastatic breast cancer cell line by many studies, but 
later was considered as a melanoma cell line due to its 
karyotype  and  microsatellite  similar  to  those  of  the 
M14 melanoma cell line (25). However, multiple lines 
of evidence suggest that the MDA-MB-435 cell line is 
still a poorly differentiated, metastatic breast cancer 
cell line. Firstly, this cell line has a female origin with 
two X chromosomes and without Y chromosome (25), 
while the initial M14 melanoma cell line had a male 
origin (26). Furthermore, MDA-MB-435 cells can ex-
press epithelial markers and secrete milk proteins and 
lipids  under  certain  experimental  conditions.  When 
the  nm23  metastasis  suppressor  is  ectopically  ex-
pressed  in  MDA-MB-435  cells,  these  cells  exhibit  a 
similar morphology to normal breast epithelial cells, 
including acinus formation in three-dimensional cul-
ture and production of milk proteins (27, 28). In this 
study,  we  showed  that  knockdown  of  TWIST  in 
MDA-MB-435 cells resulted in ER expression. This 
finding  should  serve  as  an  additional  evidence  to 
support  the  breast  cancer  origin  of  MDA-MB-435 
cells. 
 
 
Fig. 6. A model for the repression of ERα expression by TWIST. TWIST protein (T) binds to E-boxes in the 7th intron of ESR1 
gene as homodimer or heterodimer with E12 or TWIST2, which recruits NuRD complex to decrease H3K9 acetylation (Ac) and increase 
H3K9 methylation (Me1) levels, resulting in transcriptional repression of ERexpression. Int. J. Biol. Sci. 2012, 8 
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During the preparation of this paper, Vesuna et 
al. reported that TWIST also bound a different DNA 
region  adjacent  to  the  ESR1  gene  promoter  and  re-
cruited  the  HDAC1-DNMT3B  repressor  complex  to 
repress ER expression (29). This study demonstrated 
that TWIST expression in ER-positive cells induced 
tamoxifen  resistance,  while  TWIST  knockdown  in 
ER-negative  breast  cancer  cells  could  restore  ER 
expression and the inhibitory effect of tamoxifen on 
estrogen-stimulated  cell  growth.  Therefore,  our  in-
dependent findings are conceptually consistent with 
this recent study but provide another completely dif-
ferent molecular mechanism responsible for TWIST to 
repress ER expression.  
In conclusion, this study demonstrated that the 
expression and repression of the ESR1 gene in breast 
cancer  cells  are  reversible  processes.  TWIST-NuRD 
complex-mediated repression is, at least in part, re-
sponsible  for  silencing  ER  expression  in 
TWIST-positive and ER-negative breast cancer cells. 
Therefore,  targeting  TWIST  function  may  facilitate 
restoration of ER expression and endocrine therapy 
sensitivity in these breast cancer cells.  
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